Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-PanTumor01
jRCT2031230575Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in melanoma, head and neck squamous cell carcinoma (HNSCC), gastric adenocarcinoma and 10 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate and PSA50 response rate. Started Mar 2024; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)gastric adenocarcinomagastroesophageal junction adenocarcinomaovarian cancer
Beyond the preview
Go deeper on jRCT2031230575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230575.